Olfr679, encoded by the Or56a3 gene, is part of the olfactory receptor family in Mus musculus, classified within the extensive G-protein-coupled receptor (GPCR) superfamily. These olfactory receptors are crucial for detecting odorant molecules in the nasal epithelium, initiating neuronal responses that lead to the perception of smell. Structurally, these receptors share a 7-transmembrane domain configuration, similar to many neurotransmitter and hormone receptors, and are responsible for the recognition and G protein-mediated transduction of odorant signals. The activation of olfactory receptors, including Olfr679, triggers a series of intracellular events, typically involving the modulation of second messengers like cyclic AMP (cAMP). The challenge of inhibiting Olfr679 lies in the complexity of GPCR signaling pathways and the absence of specific direct inhibitors. Consequently, the focus shifts to potential indirect inhibitors that modulate related signaling pathways or cellular processes. Beta-adrenergic receptor antagonists such as propranolol, atenolol, and metoprolol reduce cellular cAMP levels, a critical second messenger in GPCR signaling. This reduction in cAMP could indirectly affect the signaling pathways of GPCRs, including olfactory receptors like Olfr679. Additionally, calcium channel blockers like nifedipine and verapamil alter intracellular calcium levels, another key factor in GPCR signaling. Changes in calcium dynamics can indirectly influence the function of GPCRs, including olfactory receptors.
Targeting other GPCR pathways, such as those modulated by angiotensin II receptors, provides another indirect method to modulate olfactory receptor function. Antagonists like losartan and candesartan might alter the GPCR signaling environment, potentially affecting the function of receptors like Olfr679. Furthermore, alpha-2 adrenergic receptor modulation by agents like yohimbine and clonidine might also indirectly impact GPCR signaling mechanisms, including those of olfactory receptors. In conclusion, the indirect inhibition of Olfr679 involves a comprehensive understanding of GPCR biology and the interconnected nature of cellular signaling pathways. The chemicals listed offer insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr679. While direct inhibition presents significant challenges, these indirect approaches provide potential strategies for modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic antagonist, reducing cAMP levels by inhibiting beta-adrenergic receptors, potentially affecting GPCR-mediated pathways including Olfr679. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $77.00 $408.00 | 1 | |
Atenolol, a β1-adrenergic receptor antagonist, decreases cAMP levels, potentially indirectly influencing GPCR signaling pathways and impacting Olfr679 function. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $105.00 $238.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, may indirectly affect GPCR signaling by altering β1 receptor activity, potentially impacting Olfr679. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine, a calcium channel blocker, modulates intracellular calcium levels, potentially impacting GPCR-mediated pathways and indirectly affecting Olfr679. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially impacting Olfr679. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Carvedilol, with beta-adrenergic antagonist and alpha-1 blocking activity, might modulate GPCR-mediated signaling, potentially influencing Olfr679. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, affects GPCR signaling by inhibiting AT1 receptors, potentially indirectly impacting Olfr679. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $46.00 $92.00 $148.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, could indirectly modulate GPCR signaling pathways, influencing Olfr679. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling, potentially influencing Olfr679. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $180.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, which could impact Olfr679. | ||||||